Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Elise, Lepeltier"'
Autor:
Pierre Idlas, Elise Lepeltier, Guillaume Bastiat, Pascal Pigeon, Michael J. McGlinchey, Nolwenn Lautram, Anne Vessières, Gerard Jaouen, Catherine Passirani
Publikováno v:
Langmuir. 39:1885-1896
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ec82f75909d6d6671a467c23de6f39f
https://doi.org/10.1021/acs.langmuir.2c02910
https://doi.org/10.1021/acs.langmuir.2c02910
Autor:
Elise Lepeltier, Vincent Levet, Tu Lee, Nathalie Mignet, Jianliang Shen, Hicham Fenniri, Yohann Corvis
Publikováno v:
Frontiers in Chemistry, Vol 8 (2020)
Externí odkaz:
https://doaj.org/article/228575f3315f4cf2acfa4b246ed92bb9
Autor:
Milad Baroud, Elise Lepeltier, Yolla El-Makhour, Nolwenn Lautram, Jerome Bejaud, Sylvain Thepot, Olivier Duval
Publikováno v:
Pharmaceuticals, Vol 14, Iss 12, p 1317 (2021)
5-Azacitidine, a cytidine analogue used as a hypomethylating agent, is one of the main drugs for the treatment of myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML) in the elderly. However, after administration, it exhibits several lim
Externí odkaz:
https://doaj.org/article/b21738572f654089beb9c95d5a35e179
Autor:
Abdallah Ladaycia, Gilles Gasser, Ursula Rothlisberger, François Mouvet, Jennifer Keiser, Valentin Buchter, Yih Ching Ong, Elise Lepeltier
Schistosomiasis is a disease of poverty affecting millions of people. Praziquantel (PZQ), with its strengths and weaknesses, is the only treatment available. We previously reported 3 lead compounds derived from oxamniquine (OXA), an old antischistoso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10ffea96bbdf24cd27fbb527353cf21e
https://hal.archives-ouvertes.fr/hal-03645191
https://hal.archives-ouvertes.fr/hal-03645191
Autor:
Duval, Milad Baroud, Elise Lepeltier, Yolla El-Makhour, Nolwenn Lautram, Jerome Bejaud, Sylvain Thepot, Olivier
Publikováno v:
Pharmaceuticals; Volume 14; Issue 12; Pages: 1317
5-Azacitidine, a cytidine analogue used as a hypomethylating agent, is one of the main drugs for the treatment of myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML) in the elderly. However, after administration, it exhibits several lim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::43bcfa12dd10449c477143d1fe9e96ad
Autor:
Yasmine Labrak, Béatrice Heurtault, Benoît Frisch, Patrick Saulnier, Elise Lepeltier, Veronique E Miron, Giulio G. Muccioli, Anne des Rieux
Publikováno v:
International journal of pharmaceutics, Vol. 618, p. 121623 (2022)
International Journal of Pharmaceutics
International Journal of Pharmaceutics, 2022, 618, pp.121623. ⟨10.1016/j.ijpharm.2022.121623⟩
International Journal of Pharmaceutics
International Journal of Pharmaceutics, 2022, 618, pp.121623. ⟨10.1016/j.ijpharm.2022.121623⟩
Impairment of oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes and chronic inflammation are key determinants of poor remyelination observed in diseases such as multiple sclerosis. For many pro-myelinating molecules, the the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b0f95aa588fb1d4fc181aa4875ce7e7
https://pubmed.ncbi.nlm.nih.gov/35231547
https://pubmed.ncbi.nlm.nih.gov/35231547
Autor:
Pierre, Idlas, Abdallah, Ladaycia, Fariba, Némati, Elise, Lepeltier, Pascal, Pigeon, Gerard, Jaouen, Didier, Decaudin, Catherine, Passirani
Publikováno v:
International Journal of Pharmaceutics
International Journal of Pharmaceutics, 2022, 626, pp.122164. ⟨10.1016/j.ijpharm.2022.122164⟩
International Journal of Pharmaceutics, 2022, 626, pp.122164. ⟨10.1016/j.ijpharm.2022.122164⟩
International audience; Ovarian cancer is one of the deadliest epithelial malignancies in women, owing to the multidrug resistance that restricts the success of conventional chemotherapy, carboplatin and paclitaxel. High grade serous ovarian carcinom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5d48292edac335c957395882e8cffe5
https://doi.org/10.1016/j.ijpharm.2022.122164
https://doi.org/10.1016/j.ijpharm.2022.122164
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics
European Journal of Pharmaceutics and Biopharmaceutics, 2021, 169, pp.220-240. ⟨10.1016/j.ejpb.2021.10.015⟩
European Journal of Pharmaceutics and Biopharmaceutics, 2021, 169, pp.220-240. ⟨10.1016/j.ejpb.2021.10.015⟩
The healthy human body is inhabited with a large number of bacteria, forming natural flora. It is even estimated that for a human body, its amount of DNA is less important that its bacterial genetic material. This flora plays major roles in the sickn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01723fe8d18efebaa0c609293e68cfc9
https://pubmed.ncbi.nlm.nih.gov/34736984
https://pubmed.ncbi.nlm.nih.gov/34736984
Publikováno v:
Cancers, Vol 13, Iss 2291, p 2291 (2021)
Cancers
Cancers, MDPI, 2021, 13 (10), pp.2291. ⟨10.3390/cancers13102291⟩
Cancers, 2021, 13 (10), pp.2291. ⟨10.3390/cancers13102291⟩
Cancers
Cancers, MDPI, 2021, 13 (10), pp.2291. ⟨10.3390/cancers13102291⟩
Cancers, 2021, 13 (10), pp.2291. ⟨10.3390/cancers13102291⟩
Simple Summary One of the primary causes of chemotherapy failure is the occurrence of cancer multidrug resistance (MDR). Uncontrolled growth of resistant tumor cells leads to metastasis and recurrence, associated with high mortalities. Ferrocifens ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a85173943efec8248a1c26c0c23cec
https://www.mdpi.com/2072-6694/13/10/2291
https://www.mdpi.com/2072-6694/13/10/2291
Autor:
Adélie Mellinger, Christine Jérôme, Elise Lepeltier, Antoine Debuigne, Vincent Pautu, Nicolas Clere, Catherine Passirani, Jérémie Riou
Publikováno v:
Cancers
Volume 13
Issue 9
Cancers, MDPI, 2021, 13 (9), ⟨10.3390/cancers13092028⟩
Cancers, Vol 13, Iss 2028, p 2028 (2021)
Cancers, 2021, 13 (9), ⟨10.3390/cancers13092028⟩
Volume 13
Issue 9
Cancers, MDPI, 2021, 13 (9), ⟨10.3390/cancers13092028⟩
Cancers, Vol 13, Iss 2028, p 2028 (2021)
Cancers, 2021, 13 (9), ⟨10.3390/cancers13092028⟩
Simple Summary Only 13 to 50% of patients with metastatic melanoma respond to new commercialized therapies. The reason why the same chemotherapeutic treatments yield different responses in patients can be attributed to the degree of multidrug resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44905689beac5eccb053bbfc07370710